具有吡唑并苯并咪唑配体的细胞毒钌(II)配合物可抑制 VEGFR2 磷酸化。
Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
机构信息
National Institute of Biomedical Genomics, Kalyani 741251, India.
出版信息
Inorg Chem. 2021 Dec 6;60(23):18379-18394. doi: 10.1021/acs.inorgchem.1c02979. Epub 2021 Nov 15.
Eight new ruthenium(II) complexes of ,-chelating pyrazolylbenzimidazole ligands of the general formula [Ru(-cym)(L)X] [where the ligand L is 2-(1-pyrazol-1-yl)-1-benzo[]imidazole () substituted at the 4 position of the pyrazole ring by Cl (), Br (), or I () and X = Cl and I] were synthesized and characterized using various analytical techniques. Complexes and were also characterized by single-crystal X-ray crystallography, and they crystallized as a monoclinic crystal system in space groups 2/ and 2/, respectively. The complexes display good solution stability at physiological pH 7.4. The iodido-coordinated pyrazolylbenzimidazole ruthenium(II) -cymene complexes (, , , and ) are more resistant toward hydrolysis and have less tendency to form monoaquated complexes in comparison to their chlorido analogues (, , , and ). The halido-substituted 2-(1-pyrazol-1-yl)-1-benzo[]imidazole ligands, designed as organic-directing molecules, inhibit vascular endothelial growth factor receptor 2 (VEGFR2) phosphorylation. In addition, the ruthenium(II) complexes display a potential to bind to DNA bases. The cytotoxicity profile of the complexes (IC ca. 9-12 μM for -) against the triple-negative breast cancer cells (MDA-MB-231) show that most of the complexes are efficient. The lipophilicity and cellular accumulation data of the complexes show a good correlation with the cytotoxicity profile of -. The representative complexes and demonstrate the capability of arresting the cell cycle in the G2/M phase and induce apoptosis. The inhibition of VEGFR2 phosphorylation with the representative ligands and and the corresponding metal complexes and shows that the organic-directing ligands and their complexes inhibit VEGFR2 phosphorylation. Besides, , , , and inhibit the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and proto-oncogene tyrosine-protein kinase (Src), capable of acting downstream of VEGFR2 as well as independently. Compounds , , , and have a lesser effect on ERK1/2 and more prominently affect Src phosphorylation. We extended the study for and in the Tg(fli1:gfp) zebrafish model and found that is more effective compared to in inhibiting angiogenesis.
八种新的钌(II)配合物,-螯合吡唑并苯并咪唑配体的一般公式[Ru(-cym)(L)X] [其中配体 L 是 2-(1-吡唑-1-基)-1-苯并[]咪唑()在吡唑环的 4 位取代氯(),溴()或碘()和 X = Cl 和 I]是使用各种分析技术合成和表征的。配合物和也通过单晶 X 射线晶体学进行了表征,它们分别结晶为单斜晶系空间群 2/和 2/。配合物在生理 pH 值 7.4 下显示出良好的溶液稳定性。碘配位的吡唑并苯并咪唑钌(II)-枯烯配合物(,,,和)对水解的抵抗力更强,并且与它们的氯类似物(,,,和)相比,形成单水合配合物的趋势较小。设计为有机导向分子的卤代取代的 2-(1-吡唑-1-基)-1-苯并[]咪唑配体抑制血管内皮生长因子受体 2(VEGFR2)磷酸化。此外,钌(II)配合物显示出与 DNA 碱基结合的潜力。配合物(IC ca. 9-12 μM 对-)对三阴性乳腺癌细胞(MDA-MB-231)的细胞毒性谱表明,大多数配合物均有效。配合物的亲脂性和细胞积累数据与 -的细胞毒性谱显示出良好的相关性。代表性配合物和证明了它们能够在 G2/M 期阻滞细胞周期并诱导细胞凋亡。代表性配体和及其相应的金属配合物和抑制 VEGFR2 磷酸化的能力表明,有机导向配体及其配合物抑制 VEGFR2 磷酸化。此外,,,,和抑制细胞外信号调节激酶 1/2(ERK1/2)和原癌基因酪氨酸蛋白激酶(Src)的磷酸化,能够作为 VEGFR2 的下游以及独立地发挥作用。化合物,,,和对 ERK1/2 的影响较小,对 Src 磷酸化的影响更为明显。我们在 Tg(fli1:gfp)斑马鱼模型中扩展了对和的研究,发现与相比,在抑制血管生成方面更有效。